Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-28

Study Completion Date

2018-06-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research project will study whether the drug telmisartan administered in conjunction with antiretroviral therapy (ART) will help reduce nervous system infection with HIV. The investigators are studying the effect of this treatment in people who have contracted HIV infection within the past three weeks, and thus have a form of HIV called acute HIV infection. The investigators will measure biological markers of immune activation in the blood and cerebrospinal fluid to see if telmisartan may reduce the spread of HIV reservoirs in affected patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease

NCT01578772

Endothelial Dysfunction

COMPLETED PHASE2

Effects of Anti-HIV Therapy on Nervous System Function

NCT00432003

HIV Infections

COMPLETED

Peripheral Reservoir of HIV DNA in Monocytes Pivotal to Cognition in HIV

NCT00782808

HIV Infections

COMPLETED

The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous System

NCT00002288

HIV Infections

COMPLETED NA

Establish and Characterize an Acute HIV Infection Cohort in a High Risk Population

NCT00796146

Acute HIV Infection

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Note regarding the primary purpose of the study: In the Study Design section, this protocol is classified as "Other", since it is specifically designed to examine the effect of telmisartan administered in conjunction with ART on the size of HIV reservoirs in the central nervous system.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute HIV Infection HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Antiretroviral Therapy (ART) only

Acute HIV-infected subjects (n=7) will be randomly assigned to a group that will receive antiretroviral therapy (the current standard of care for HIV patients) for 72 weeks.

Group Type NO_INTERVENTION

No interventions assigned to this group

ART + Telmisartan

Acute HIV-infected subjects (n=14) will be randomly assigned to a group that will receive treatment with telmisartan in addition to ART. Subjects will receive 40mg telmisartan daily for 4 weeks, followed by 80mg telmisartan daily for 44 weeks, to be taken in conjunction with ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily. After telmisartan is stopped, subjects will continue to take ART for an additional 24 weeks (total 72 weeks).

Group Type EXPERIMENTAL

Telmisartan

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telmisartan

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old
* Have protocol-defined acute HIV-1 infection
* Be part of the SEARCH 010/RV 254 study in Bangkok, Thailand
* Ability and willingness to start ART immediately after diagnosis
* Availability for follow-up for the duration of the planned study
* Systolic blood pressure ≥ 110 mmHg
* Agree to undergo lumbar puncture at weeks 0, 48 and 72
* Ability and willingness to provide informed consent. Subjects must understand the study and sign the consent form. Persons who cannot read will have the consent form read to them by a member of the study staff and may then give informed consent by using making a thumb print.

Exclusion Criteria

* Pregnancy (current or within the last 6 months) or breastfeeding
* Uncontrolled hypertension
* Use of thiazolidinediones or other angiotensin receptor blockers class \[losartan, irbesartan, olmesartan, valsartan, candesartan (washout permitted)\]
* Screening laboratory values: absolute neutrophil count \< 750 cells/mm3, hemoglobin \<10 gm/dL creatinine clearance \<30 mL/min (estimated by the Cockcroft-Gault equation using ideal body weight)
* Known renal artery stenosis
* Known cirrhosis or severe liver disease
* Unstable coronary artery disease/angina or decompensated congestive heart failure
* Any history of intolerance to any angiotensin receptor blocker
* Need for ongoing potassium supplementation
* Any contraindication to lumbar puncture such as history of bleeding diathesis or cerebral mass lesion

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No